证券代码:600789 证券简称:鲁抗医药 公告编号:2026-006 山东鲁抗医药股份有限公司 关于"提质增效重回报"行动方案的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大 遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 为贯彻落实国务院《关于进一步提高上市公司质量的意见》，积极响应上海 证券交易所《关于开展沪市公司"提质增效重回报"专项行动的倡议》等相关要 求，山东鲁抗医药股份有限公司（以下简称"公司"）结合自身发展战略和实际 经营情况，制定"提质增效重回报"行动方案。具体方案如下： 一、聚焦主营业务，提升经营质量 公司属于国有控股综合性医药企业，主要从事医药及生物制造产品的研发、 生产和销售等业务，产品涉及医药制剂、原料药、中成药、动植物保健、合成生 物等领域。公司以发展生态医药、服务人类健康为使命，制造优质安全高效的药 品，服务人民医疗健康事业。 未来，公司将立足生物医药及生物制造主业，聚焦业务结构优化与经营质效 提升，系统构建高质量发展体系。在产品创新方面，公司将落实研发"精品工程" 的整体要求，以丰富产品管线为基础，以充实产线负荷为依托，强化"两优势、 ...

Core Insights - LuKang Pharmaceutical (600789) is actively advancing automation, digitalization, and intelligence in its operations, significantly enhancing equipment automation and intelligence levels, and accelerating high-end and intelligent development [1] Group 1: Automation and Digitalization Initiatives - The company has optimized resource allocation and management capabilities, establishing smart factories and intelligent enterprises to enhance core competitiveness and achieve significant growth [1] - By 2025, LuKang Pharmaceutical aims to be recognized as an excellent intelligent factory by the Ministry of Industry and Information Technology, and has completed the construction of two digital pilot workshops, SY25 and SS16, which have increased production capacity and labor productivity [1] - The SS16 project increased output from 7,000 tons to 8,000 tons, with labor productivity rising from 2.75 million to 4.4 million yuan per employee, while SY25 is expected to achieve a labor productivity of 4.32 million yuan per employee [1] Group 2: Smart Warehouse and Production Automation - In 2025, the company completed the construction of an intelligent warehouse with a total area of 15,562.70 m² and over 23,000 storage locations, capable of storing approximately 300,000 items [2] - The intelligent warehouse features automated functions such as inbound and outbound logistics, and integrates with WMS, ERP, TMS, and AGV systems for efficient management and space utilization [2] - LuKang Pharmaceutical implemented six automation enhancement projects in its production lines, including advanced equipment like AGV transporters and high-speed capping machines, which improved overall equipment levels and reduced labor intensity [2] Group 3: Smart Management Platform and Future Goals - The company has developed a smart operational management platform centered around ERP, integrating various management systems to streamline financial, sales, procurement, and production processes [3] - By 2025, LuKang Pharmaceutical plans to fully implement quality management system modules and expand RPA applications to 35 scenarios, enhancing operational efficiency and decision-making capabilities [3] - During the 14th Five-Year Plan period, the company will promote AI-driven business innovations and accelerate its digital transformation to ensure industry-leading standards in smart construction and high-quality development [3]

Core Viewpoint - The company anticipates a significant decline in net profit for the fiscal year 2025, projecting a decrease of 63.26% to 72.13% compared to the previous year, primarily due to non-recurring gains and market pressures [2][4]. Group 1: Performance Forecast - The performance forecast applies to a scenario where the company achieves profitability but experiences a net profit decline of over 50% compared to the same period last year [2]. - For the fiscal year 2025, the company expects a net profit attributable to shareholders of the parent company to be between 110 million and 145 million yuan, representing a year-on-year decrease of 24.962 million to 28.462 million yuan [4]. - The forecasted net profit, excluding non-recurring gains and losses, is expected to be between 80 million and 118 million yuan, reflecting a year-on-year decrease of 9.058 million to 12.858 million yuan [4]. Group 2: Previous Year’s Performance and Financial Status - In the previous year, the total profit was 433.9014 million yuan, with a net profit attributable to shareholders of the parent company at 394.6157 million yuan [6]. - The net profit attributable to shareholders, excluding non-recurring gains and losses, was 208.5835 million yuan, with earnings per share at 0.44 yuan [6]. Group 3: Reasons for Performance Decline - The decline in performance is primarily attributed to the impact of non-recurring gains from the previous year, where significant asset disposal gains were realized due to the completion of land transfer procedures [6]. - Market factors such as reduced product demand, intense industry competition, and price reductions from national procurement policies have pressured overall industry profits, leading to a decline in revenue and gross profit for the company [6]. - Strategic investments in high-quality development and increased R&D expenditures for innovative drugs and high-end formulations have also contributed to short-term cost pressures affecting profits [6].

Core Viewpoint - Lu Kang Pharmaceutical (600789) expects a significant decrease in net profit for 2025, projecting a range of 110 million to 145 million yuan, representing a year-on-year decline of 63.26% to 72.13% [1] Financial Performance - The anticipated decrease in profit is primarily attributed to the impact of non-recurring gains and losses, market factors, and short-term cost pressures related to strategic investments [1] - The previous year's performance was boosted by substantial asset disposal gains from the completion of land transfer procedures, leading to significant fluctuations in this year's results [1] Industry Context - The pharmaceutical industry is facing overall profit pressure due to slowing product market demand, intense competition, and price reductions from national centralized procurement policies [1] - Traditional human formulation products are experiencing significant changes in terminal demand, leading to pressures on volume and pricing adjustments, which have negatively impacted revenue and gross profit [1] Strategic Investments - To promote high-quality development, the company is increasing its investment in research and development, focusing on innovative drugs, high-end formulations, and synthetic biology [1] - The increase in amortization expenses related to previously approved technical assets and the sustained high level of R&D investment are expected to have a short-term negative impact on profits [1]

Core Viewpoint - The company, LuKang Pharmaceutical, anticipates a significant decline in net profit for the year 2025, projecting a decrease of 24.96 million to 28.46 million yuan compared to the previous year, which translates to a year-on-year reduction of 63.26% to 72.13% [1] Financial Performance - The expected net profit for 2025 is estimated to be between 110 million yuan and 145 million yuan [1] - This represents a substantial decrease from the previous year's figures, indicating potential challenges in the company's financial performance [1]

Core Viewpoint - LuKang Pharmaceutical (600789.SH) expects a significant decline in net profit for the fiscal year 2025, projecting a net profit attributable to shareholders of the parent company between 110 million to 145 million yuan, representing a decrease of approximately 249.62 million to 284.62 million yuan compared to the previous year, which translates to a year-on-year decline of 63.26% to 72.13% [1] Financial Summary - The projected net profit for 2025 is estimated to be between 110 million to 145 million yuan [1] - The expected decrease in net profit compared to the previous year is between 249.62 million to 284.62 million yuan [1] - The year-on-year percentage decline in net profit is forecasted to be between 63.26% and 72.13% [1]

Group 1 - The company, Lu Kang Pharmaceutical (600789.SH), expects to achieve a net profit attributable to shareholders of the parent company between 110 million to 145 million yuan for the fiscal year 2025 [1] - This represents a decrease of 249.62 million to 284.62 million yuan compared to the previous year [1] - The year-on-year decline in net profit is projected to be between 63.26% to 72.13% [1]

证券代码:600789 证券简称:鲁抗医药 公告编号:2026-005 ●预计 2025 年度实现归属于母公司所有者的净利润 11,000 万元-14,500 万 元。与上年同期相比，同比减少 63.26%-72.13%。 ●预计 2025 年度实现归属于母公司所有者的扣除非经常性损益的净利润 8,000万元-11,800 万元。与上年同期相比，同比减少 43.43%-61.65%。 一、本期业绩预告情况 （一）业绩预告期间 2025 年 1 月 1 日至 2025 年 12 月 31 日。 （二）业绩预告情况 山东鲁抗医药股份有限公司 2025 年年度业绩预告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗 漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： ●本期业绩预告适用于实现盈利，且净利润与上年同期相比下降50%以上的情 形。 三、本期业绩预减的主要原因 （一）非经常性损益的影响。上年同期公司南厂区土地办理完成移交手续， 土地完成整体移交后产生大额的资产处置收益，导致本期业绩较上年同期变动幅 度较大。 （二）市场因素影响。受产品市场需求放缓、行业竞争激 ...

Core Viewpoint - Lu Kang Pharmaceutical (600789.SH) expects a significant decline in net profit for the fiscal year 2025, projecting a range of 110 million to 145 million yuan, which represents a year-on-year decrease of 63.26% to 72.13% [1] Group 1: Financial Performance - The anticipated net profit for 2025 is estimated to be between 110 million and 145 million yuan [1] - This projection indicates a substantial decrease in profitability compared to the previous year [1] Group 2: Reasons for Performance Change - The decline in profit is attributed to several factors, including the previous year's substantial asset disposal gains from the transfer of land in the southern plant area [1] - Market demand has slowed down, and price reductions due to centralized procurement have put pressure on both volume and pricing [1] - Increased amortization of research and technical assets has also contributed to the financial downturn [1]

证券之星消息，1月26日化学制药板块较上一交易日下跌0.18%，富祥药业领跌。当日上证指数报收于 4132.61，下跌0.09%。深证成指报收于14316.64，下跌0.85%。化学制药板块个股涨跌见下表： 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。 从资金流向上来看，当日化学制药板块主力资金净流入11.16亿元，游资资金净流入2.2亿元，散户资金净 流出13.37亿元。化学制药板块个股资金流向见下表： | 代码 | 名称 | 主力净流入 (元) | 主力净占比 游资净流入 (元) | | 游资净占比 散户净流入 (元) | | 散户净占比 | | --- | --- | --- | --- | --- | --- | --- | --- | | 600789 | 鲁抗医药 | 26653 | 29.72% | -1.98亿 | -14.72% | -2.01 乙 | -14.99% | | 300723 | 一品红 | 1.00 Z | 13.23% | 2678.72万 | 3.54% | -1.27 Z | -16.76% ...